CA-INSEEGO-CORP
26.7.2022 13:03:16 CEST | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG) announced today that the Inseego Wavemaker™ FX2000 5G indoor router is now being sold to customers on the Three Sweden network. Three Sweden is part of Three Group Europe, which includes networks in Austria, Denmark, Italy, Ireland, Sweden and the United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005524/en/
The award-winning FX2000 fixed wireless access (FWA) router can deliver gigabit speeds for fast and reliable internet access, along with Wi-Fi 6 for up to 30 devices, making it ideal for remote work, streaming and gaming. With its small, elegant design and simple setup, it fits into any environment, from home offices to summer cottages.
“We’re proud to provide this fixed wireless access solution to Three Sweden and their customers,” said Simon Rayne, senior vice president and managing director, UK, EMEA, and Asia-Pacific for Inseego. “This is the first commercial launch of our FX2000 with a European carrier, and we look forward to many more. Our 5G solutions are changing the way millions of people stay connected at home, in the office, and on the move.”
“This router is an excellent choice for our customers who want the speed and simplicity of 5G home internet,” said Rune Pedersen, CCO Consumer Market at Three Sweden. “Combined with our unlimited 3Bredband Max, it’s an easy, affordable way to plug into the power of new 5G experiences.”
Speed, simplicity and flexibility: With its small footprint and low profile, the FX2000 fits into any setting. It can be placed on a tabletop or desktop and moved easily when relocating to a new home or office.
Easy setup and management: The FX2000 can be set up by anyone (no service technician needed) in just a few minutes. The Inseego Mobile smartphone app makes it easy to choose the best placement and manage the FX2000 with user-friendly control settings.
Best-in-class performance: With Inseego’s industry-leading antenna and RF technology, the FX2000 can deliver peak 5G speeds over 1 Gbps (depending on network coverage), along with fallback to Cat 22 LTE. Sustained high throughput and low latency 5G connections are ideal for applications such as video conferencing, streaming media, AR/VR and cloud computing. The FX2000 supports dual-band Wi-Fi 6 for up to 30 connected devices, as well as an ethernet LAN port and USB port, to connect up to 32 devices simultaneously. The ethernet LAN port can also be connected to other routing devices.
Enterprise-grade security: Designed and developed in the U.S. with multiple layers of advanced security, the FX2000 safeguards data with advanced encryption, hacker prevention, password protection, OpenVPN, guest Wi-Fi network and more. Robust authentication protects against cyber threats and allows customers to connect with confidence.
To learn more about Inseego 5G products and solutions, please go to inseego.com .
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Inseego’s mobile broadband, fixed wireless access (FWA) solutions and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of innovative products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service provider, enterprise, and government entities worldwide. www.inseego.com #Putting5GtoWork
Inseego 5G FX2000 chipset: Qualcomm® Snapdragon® X55 5G Modem-RF System.
©2022. Inseego Corp. All rights reserved. The Inseego name and logo name and logo are registered trademarks and Wavemaker is a trademark of Inseego Corp. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005524/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom